Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q1 2025 Earnings Call Transcript
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q1 2025 Earnings Call Transcript May 6, 2025Ultragenyx Pharmaceutical Inc. misses on earnings expectations.
Ultragenyx Pharmaceutical Inc. (RARE)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | BIT Capital GmbH Jan Beckers | 21,655 | $784,128 | -28% | 0.07% |
| 2. | Bayforest Capital Theodoros Tsagaris | 9,190 | $183,476 | +193% | 0.15% |
| 3. | Antipodes Partners Jacob Mitchell | 1,568 | $56,782 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $43.63 | 5,000 | Officer, Director | 472,479 | 2019-09-11 | Filing | |
| $52.96 | 1,647 | Officer, Director | 2,559,741 | 2017-08-28 | Filing | |
| $52.40 | 5,853 | Officer, Director | 2,558,094 | 2017-08-28 | Filing | |
| $21.00 | 175,000 | Large Shareholder, Other | 3,260,240 | 2014-01-31 | Filing | |
| $21.00 | 4,500 | Officer | 84,255 | 2014-01-30 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $39.24 | 520 | 71,530 | 2025-05-05 | Filing | ||
| $35.11 | 242 | 71,680 | 2025-04-21 | Filing | ||
| $40.40 | 1,785 | 106,169 | 2025-03-06 | Filing | ||
| $42.10 | 6,028 | 265,238 | 2025-03-03 | Filing | ||
| $42.10 | 12,846 | 75,287 | 2025-03-03 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 9,996,226 | $361,963,343 | 0.01% | |
| 2. | 6,158,266 | $222,990,812 | 0% | |
| 3. | 2,055,200 | $74,418,792 | 0.16% | |
| 4. | 1,701,493 | $61,611,061 | 0.02% | |
| 5. | 1,409,199 | $51,957,478 | 0.06% |
News See All
Billionaire Stanley Druckenmiller's Top 10 Stocks Picks with Huge Upside Potential
Wall Street is overflowing with data. If companies are not releasing their earnings, economic data flows almost daily.
11 Best Gene Therapy Stocks to Buy According to Analysts
Gene therapy is a medical approach that entails changing or modifying genes to treat or prevent disease.
10 Best Mid Cap Biotech Stocks to Buy
On March 6, Jared Holz, Mizuho health care equity strategist, appeared on CNBC's 'Power Lunch' to discuss investing in biotech and the oversaturation in the sector.
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q4 2024 Earnings Call Transcript
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q4 2024 Earnings Call Transcript February 13, 2025Ultragenyx Pharmaceutical Inc. misses on earnings expectations.
12 Biotech Stocks with the Biggest Upside Potential
While 2024 was a "challenging" year for biotech stocks, JPMorgan is of the view that some names in the industry may be poised for considerable upside in the coming months.
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q3 2024 Earnings Call Transcript
Operator: Good afternoon and welcome to the Ultragenyx Third Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
What Makes Ultragenyx Pharmaceutical (RARE) an Exciting Investment Opportunity?
Baron Funds, an investment management company, released its “Baron Health Care Fund” third quarter 2024 investor letter. A copy of the letter can be downloaded here.
10 Best Mid-Cap Healthcare Stocks To Buy Now
According to projections by ReportLinker, the market for healthcare services will increase from $7.5 trillion in 2022 to $7.975 trillion in 2023.
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q2 2024 Earnings Call Transcript
Operator: Good afternoon, and welcome to the Ultragenyx Second Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode.